Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck
Latest Information Update: 25 Feb 2016
At a glance
- Drugs Terameprocol (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Erimos Pharmaceuticals
- 04 Oct 2005 New trial record.